Bharat Biotech's `Covaxin' only vaccine to be 65.2% effective against Delta variant: The Lancet

The safety and efficacy analysis data from Phase III clinical trials of Covaxin has been peer-reviewed and published in The Lancet.

By Newsmeter Network  Published on 12 Nov 2021 2:57 AM GMT